Cerebral microbleeds (CMBs) may be markers of intracerebral bleeding risk in patients receiving antithrombotic drugs. This study aimed to analyze CMBs and white matter hyperintensities (WMHs) in patients taking aspirin or clopidogrel.
Introduction
Cerebral microbleeds (CMBs) are focal deposits of hemosiderin breakdown products that occur due to earlier leakages of blood from small vessels in the brain. [1] The CMBs can be detected as small, round, homogenous, low-intensity lesions by magnetic resonance imaging (MRI) using T2 * -weighted gradient-recalledecho (GRE) and T2 * -weighted angiography (SWAN) sequences. [2] [3] [4] The incidence of CMBs is around 4 to 5% in the healthy population but can exceed 50% in patients with cerebrovascular disease (CVD), and these lesions are thought to be subclinical markers of the risk of stroke and dementia. [1] In addition to their association with future macroscopic hemorrhage and stroke, [5] [6] [7] [8] CMBs have also been associated with ischemic stroke, increasing age, male sex, low serum triglycerides, Alzheimer's disease, trauma, inflammatory conditions, and genetic disorders. [9] [10] [11] [12] [13] [14] [15] [16] Aspirin and clopidogrel are antiplatelet agents widely used in the primary and secondary prevention of thrombotic CVD or cardiovascular disease, including acute coronary syndrome. [17] However, there is an evidence that antiplatelet agents are associated with an increased risk of intracerebral hemorrhage. [18] [19] [20] Interestingly, the prevalence of CMBs has been reported to be higher in patients treated with antiplatelet drugs compared with nonusers. [21] Furthermore, a systematic review of published and unpublished data concluded that antiplatelet drug use was associated with an increased prevalence of CMBs in patients with intracerebral hemorrhage, ischemic stroke or transient ischemic attack (TIA). [22] In addition, CMBs were more prevalent in antiplatelet drug users with intracerebral hemorrhage than in matched antiplatelet drug users without intracerebral hemorrhage or in patients with intracerebral hemorrhage unrelated to antiplatelet drugs, suggesting that CMBs are associated with antiplatelet-related intracerebral hemorrhage. [23] This was supported by the observation that, in patients with ischemic stroke treated with antithrombotic agents, an increased number of CMBs was associated with elevated risks of subsequent intracerebral hemorrhage and death from intracerebral hemorrhage. [24] The presence of CMBs may also be a risk factor for intracerebral hemorrhage related to warfarin, an antithrombotic agent with a different mechanism of action to aspirin and clopidogrel. [25] Indeed, warfarin use was found to enhance the prevalence of CMBs in patients with intracerebral hemorrhage but not ischemic stroke. [22, 26] However, some studies have concluded that antiplatelet drug therapy has no effect on the frequency of CMBs, [25] [26] [27] while others have suggested that the effect is mediated only on deep CMBs and not lobar CMBs. [28] White matter hyperintensities (WMHs) are lesions detectable by MRI that are generally regarded as indicators of cerebral small vessel disease. [29] The WMHs are associated with an elevated risk of stroke, dementia, and death [30] as well as poorer functional recovery after ischemic stroke. [29] Several studies have identified an association between WMHs and CMBs in healthy subjects as well as in subjects with primary or recurrent stroke. [9, [31] [32] [33] [34] However, the characteristics of the association between WHMs and CMBs in patients receiving aspirin and clopidogrel have yet to be compared in detail.
The aim of this study was to examine the associations of CMBs with WMH characteristics and intracerebral bleeding events in patients with stroke or TIA receiving aspirin or clopidogrel.
Materials and methods

Patients
This was a retrospective study. Patients with ischemic CVD treated at the Affiliated Hospital of Inner Mongolia Medical University, China, between July 2010 and July 2015 were included in this study. The inclusion criteria were: First, diagnosed with stroke or TIA. Second, had received treatment with aspirin (75 mg/day) or clopidogrel (75 mg/day) for more than 1 year. The exclusion criteria were: First, had received previous anticoagulant or thrombolytic therapy. Second, had received aspirin combined with clopidogrel.Third, cerebral amyloid angiopathy. Fourth, motion artifacts in the MRI examinations. Fifth, incomplete data. Patients receiving aspirin (aspirin group) and clopidogrel (clopidogrel group) were matched for gender and age. The study was approved by the Ethics Committee of Inner Mongolia Medical University. Due to the retrospective nature of the analysis, informed consent from the patients was waived.
MRI examination
The MRI examinations of the brain were performed on a 3.0-Tesla MR scanner (SignaHDx, GE Healthcare, Chicago, IL The MRI images were independently evaluated by 2 authors (HXY and CHB) who were blinded to the patients' clinical profiles. The number of microbleeds and the grading score for WMH were determined by consensus. Lesions within the sulcal areas and areas of symmetrical hypodensity in the globus pallidus, which were likely to represent adjacent pial blood vessels and calcification, respectively, were excluded. The degree of CMBs was classified using a scoring system [35] with 4 grades: absent (0), mild (1-5), moderate (5-10), and severe (>10). The severity of WMH on T2 * -weighted images was classified as punctate foci, foci starting to show confluence, or large confluent areas, as previously described. [36] We evaluated vascular risk factors according to Orken et al. [26] Hypertension was considered to be present when a patient had received antihypertensive treatment before admission or when hypertension was diagnosed during a hospital stay with systolic and diastolic blood pressures of at least 140 and 90 mm Hg, respectively, on multiple occasions. Diabetes mellitus (DM) was diagnostically defined as a history of DM with or without current hypoglycemic treatment or 2 fasting plasma glucose levels of 126 mg/dL or higher. A diagnosis of hyperlipidemia was made if the fasting serum total cholesterol level was > 220 mg/dL or the patient was currently undergoing cholesterol-lowering therapy. A history of smoking was noted when a subject was either a current smoker or an ex-smoker who had quit smoking less than 5 years before admission. Addiction to alcohol was considered as a risk factor if current consumption reached 300 g/week.
Statistical analysis
Data were analyzed using SPSS for Windows version 16.0 (SPSS Inc, Chicago, IL). Continuous variables are expressed as the means ± standard deviation (SD) and were compared between groups by Student t test. Categorical variables are expressed as frequencies and percentages and were compared between groups by the Chi-squared test or Fisher's exact test. Multivariate logistic stepwise regression analysis was used for subgroup analysis, with calculations of odds ratios (ORs) and 95% confidence intervals (CIs). Univariate logistic regression analysis was used to analyze the factors associated with CMBs and macroscopic bleeding, with calculations of ORs and 95% CIs. Variables with P < .05 were included in the multivariate enter analyses. Continuous variables were converted into categorical variables. Statistical significance was established using a conventional P < .05 level.
Results
Baseline characteristics of the study participants
A total of 370 patients (180 in the aspirin group, 190 in the clopidogrel group) were enrolled and 150 patients in each group were matched for gender and age. The baseline characteristics of patients before and after matching are summarized in Table 1 . No patients had acute coronary syndrome. No significant differences were found in age, gender, nationality or prevalences of hypertension, coronary artery disease, DM, hyperlipidemia, smoking, alcohol addiction, previous stroke or previous coronary angioplasty between the aspirin-treated patients and clopidogreltreated patients ( Table 1 ), suggesting that the 2 groups were well Medicine matched for all clinical characteristics and potential confounding factors. In addition, there were no significant differences between the 2 groups in the prevalences of CMBs and macroscopic intracerebral bleeding (Table 1) .
Association of macroscopic bleeding with the presence of CMBs
Nearly half the patients with CMBs in both the aspirin group (45%) and clopidogrel group (47%) had macroscopic bleeding ( Table 3 ). Table 4 showed that age ≥70 years (OR, 2.27, 95% CI, 1.14-4.52, P = .02), hypertension (OR, 3.19, 95% CI, 1.89-5.39, P < .001), DM (OR, 2.91, 95% CI, 1.61-5.27, P < .001), WMHs (OR, 2.04, 95% CI, 1.09-3.79, P = .03), and 5 years of treatment (OR, 0.48, 95% CI, 0.27-0.85, P = .01) were independently associated with MCBs. Treatment (aspirin vs clopidogrel) was not associated in the univariate analysis (P = .63). 
Multivariate analyses of CMBs according to aspirin and clopidogrel
Multivariate analyses of macroscopic bleeding according to aspirin and clopidogrel
Discussion
A notable finding of the present study was that CMBs occurred in 40.0% of patients taking aspirin for at least 1 year and 30.7% of patients taking clopidogrel for at least 1 year, with statistical analysis revealing no significant difference between groups. In both the groups, the frequencies of WMHs and macroscopic bleeding were higher in patients with CMBs than in those without CMBs. Furthermore, patients treated with either antiplatelet Table 3 Analysis of the association of cerebral microbleeds and macroscopic bleeding with the duration of treatment. There is some debate regarding whether antiplatelet drug use increases the risk of CMBs. Some previous studies have suggested that the prevalence of CMBs may be elevated in patients treated with antiplatelet drugs in comparison with nonusers, particularly those with intracerebral hemorrhage, ischemic stroke or TIA. [21, 22, 37] However, not all investigations have observed an influence of antiplatelet agents on the frequency of CMBs, [25] [26] [27] and some have concluded that the effect was mediated only on deep CMBs and not lobar CMBs. [28] The present study was not designed to assess whether therapy with aspirin or clopidogrel for at least 1 year was associated with an enhanced risk of CMBs compared with nonusers. However, the prevalences of CMBs in the aspirin group (40.0%) and clopidogrel group (30.7%) were broadly in keeping with other studies of patients with CVD receiving therapy with antiplatelet agents. For example, a metaanalysis determined that the incidence of CMBs in patients taking antiplatelet drugs was 66.7% (range, 33.3-93.3%; pooled from 12 studies) in those with intracerebral hemorrhage and 32.1% (range, 14.3-52.9%; pooled from 11 studies) in those with cerebral infarct or TIA. [22] Some reports have suggested that CMB risk may be elevated by aspirin use in comparison to use of other inhibitors of platelet aggregation. [18, 21, 38] However, in the present study, there was no significant difference in the prevalence of CMBs between the aspirin group and clopidogrel group, and the multivariate analyses showed that there were no differences between aspirin and clopidogrel. This is in line with previous studies that showed no difference in bleeding recurrence between those 2 drugs, [39, 40] but this is controversial. [41] Further clinical investigations are merited to definitively establish whether or not aspirin is associated with a heightened risk of CMBs compared with clopidogrel or other inhibitors of platelet aggregation.
We observed that the presence of CMBs was significantly associated with the prevalence and severity of WMHs. Consistent with our observations, numerous other studies have reported an association between the severity of WMHs and CMBs, both in healthy subjects and in patients with stroke. [9] [10] [11] [31] [32] [33] [34] [42] [43] [44] The relationship between the distribution of CMBs and WMH has also been explored, with previous investigations reporting associations of WMHs with deep, lobar and diffuse (i.e. both deep and lobar) CMBs. [11, 43, 45] Interestingly, a recent study concluded that although the presence of CMBs was independently associated with the severity of periventricular WMHs, the relationship with deep WMHs was found only in patients with hypertension. [46] An important finding of our study was that the presence of CMBs was strongly associated with intracerebral bleeding. This is in agreement with previous research indicating that the number of CMBs in patients with ischemic stroke treated with antithrombotic agents was related to increased risks of both intracerebral hemorrhage and death from intracerebral hemorrhage. [24] Another report found that, compared with controls, patients with ischemic CVD treated with aspirin for >1 year had higher frequencies of both CMBs (40% vs 12%) and intracerebral hemorrhage (28% vs 1%). [47] Furthermore, in patients taking an antiplatelet drug, CMBs were detected more frequently in those with intracerebral hemorrhage than in those without intracerebral hemorrhage, implying that CMBs are associated with antiplatelet-related intracerebral hemorrhage. [23] The CMBs may also be a risk factor for intracerebral hemorrhage related to warfarin, another antithrombotic agent. [22, 25, 26] Interestingly, incident intracerebral hemorrhage was reported to be associated with higher numbers of total, deep and paraventricular WMHs, [48] supporting the relationship between CMBs, WMHs, and macroscopic bleeding observed in our study.
The present study also determined that CMBs and intracerebral bleeding were strongly associated with the duration of antiplatelet therapy. A previous investigation also found that the frequency of CMBs was higher in patients with ischemic CVD treated with aspirin for >5 years than in those treated for 5 years. [47] A relationship between duration of aspirin therapy (>10 years vs 10 years) and deep or infratentorial microbleeds was also reported, but this effect became nonsignificant after adjustment for hypertension and other factors. [49] In elderly subjects, aspirin use for >5 years did not Ge et al. Medicine (2019) 98:9 www.md-journal.com enhance the risk of CMBs. [50] In addition, a study showed that the bleeding events tend to concentrate around the therapeutic switch, but the present study did not include patients who switched treatment. [51] Furthermore, the present study did not examine the resistance to aspirin or clopidogrel. Additional study is needed to confirm whether the duration of antiplatelet therapy affects the risk of CMBs. Resistance markers such as platelet reactivity, pharmacometabolomics, and microRNAs should also be examined. [51] [52] [53] [54] This study has some limitations. First, this is a retrospective study and so is prone to information bias and selection bias. Also, since the study was not prospective in design, strong evidence regarding the associations between CMBs and clinical outcomes such as intracerebral hemorrhage and mortality could not be obtained. Second, this was a single-center study, so the generalizability of the findings is not known. Third, although the sample size was not particularly small, the study may have been underpowered to detect certain differences between groups. Fourth, unknown confounding factors not included in the analysis may have influenced the results. Fifth, the distributions of CMBs and WMHs and their associations were not explored. Sixth, the exact time at bleeding event occurrence could not be determined; this will be examined in a future prospective trial. Finally, hypertension might influence the results and future studies should be conducted independently in hypertensive and non-hypertensive subjects. In addition, there was no difference between aspirin and clopidogrel. As a retrospective analysis, there was no data about optimal treatment or compliance.
In conclusion, our data indicate that the presence of CMBs in patients taking aspirin or clopidogrel with ischemic CVD is associated with elevated risks of both WMHs and macroscopic bleeding. Furthermore, the duration of antiplatelet therapy may also influence the prevalences of CMBs and macroscopic hemorrhage.
